CN Patent

CN118251220A — 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用

Assigned to Jiangsu Aosaikang Pharmaceutical Co Ltd · Expires 2024-06-25 · 2y expired

What this patent protects

本发明公开了作为c‑Met抑制剂的含嘧啶基团的三并环类化合物的组合物及其制备方法和应用，其中含嘧啶基团的三并环类化合物结构式如式(I)所示。

USPTO Abstract

本发明公开了作为c‑Met抑制剂的含嘧啶基团的三并环类化合物的组合物及其制备方法和应用，其中含嘧啶基团的三并环类化合物结构式如式(I)所示。

Drugs covered by this patent

capmatinib-hydrochloride (CAPMATINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN118251220A
Jurisdiction: CN
Classification: —
Expires: 2024-06-25
Drug substance claim: No
Drug product claim: No
Assignee: Jiangsu Aosaikang Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.